Back

Implementation of hfa-icos risk score in patients with non-hodgkin lymphoma undergoing non-pegylated doxorubicin therapy

19 June 2026 (14:15 - 15:15)
Organised by: Logo
Congress Presentation Part of: Stratifying the risk of cardiotoxicity (2) Stratification, Prevention and Monitoring Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Ilaria Torre

Cristo Re Hospital, Rome (Italy)

8 More presentations in this session

Presentation thumbnail
Comparative performance of biomarker-based and biomarker-free HFA-ICOS models for predicting anthracycline-related cardiotoxicity
Doctor C. Madaudo (Palermo, IT)
Abstract Slides
Presentation thumbnail
Incorporating poor oral health into pre-chemotherapy heart failure association/international cardio-oncology society (HFA-ICOS) baseline cardiovascular risk stratification
Doctor A. Basuoni (Muscat, OM)
Abstract Slides
Presentation thumbnail
Prognostic utility of natriuretic peptides and incremental value of the HFA-ICOS risk score in patients with multiple myeloma
Doctor N. Nakanishi (Kumamoto, JP)
Abstract Slides
Presentation thumbnail
Baseline cardiovascular characteristics and post-infusion events in patients undergoing CAR-T cell therapy
Doctor B. Aumente Rodriguez (Salamanca, ES)
Abstract Slides
Presentation thumbnail
Artificial intelligence approaches for early prediction and risk stratification of immune checkpoint inhibitor-related myocarditis: a systematic review
Miss I. Mukherjee (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Stratifying the risk of cardiotoxicity (2)

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 14:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources